Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: Implications for schizophrenia

Schizophrenia Research

Volumn 152, Issue 1, 2014, Pages 261-267

  Notarangelo, F M ^a   Wilson, E H ^b,c   Horning, K J ^a   Thomas, M A R ^a   Harris, T H ^b,d   Fang, Q ^b   Hunter, C A ^b   Schwarcz, R ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

3 Hydroxykynurenine; Astrocytes; Kynurenic acid; Microglia; Quinolinic acid

Indexed keywords

3 HYDROXYKYNURENINE; KYNURENIC ACID; KYNURENINE; PYRIMETHAMINE; QUINOLINIC ACID; SULFADIAZINE; TRYPTOPHAN;

AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; C57BL 6 MOUSE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HISTOLOGY; METABOLISM; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; TOXOPLASMOSIS; TRYPTOPHAN BRAIN LEVEL; AMINO ACID BRAIN LEVEL; AMINO ACID METABOLISM; ASTROCYTE; CELL ACTIVATION; EVALUATION STUDY; LIVER LEVEL; MICROGLIA; PARASITE LOAD; SIGNAL TRANSDUCTION; TREATMENT DURATION;

3-HK; 3-HYDROXYKYNURENINE; ASTROCYTES; IDO; INDOLEAMINE 2,3-DIOXYGENASE; KYNA; KYNURENIC ACID; MICROGLIA; QUIN; QUINOLINIC ACID; T. GONDII; TOXOPLASMA GONDII;

ANIMALS; ANTI-INFECTIVE AGENTS; BRAIN; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; FEMALE; KYNURENIC ACID; KYNURENINE; MICE; MICE, INBRED C57BL; NEUROGLIA; PYRIMETHAMINE; QUINOLINIC ACID; RNA, MESSENGER; SIGNAL TRANSDUCTION; SULFADIAZINE; TIME FACTORS; TOXOPLASMOSIS; TRYPTOPHAN;

EID: 84891632186     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.11.011     Document Type: Article

References (55)

1. Antinori A., Ammassari A., Maiuro G., Camilli G., Damiano F., Federico G., Pizzigallo E., Tamburrini E. Comparison of two medications in central nervous system toxoplasmosis in patients with AIDS. Ital. J. Neurol. Sci. 1992, 13(6):475-479.
2. Bauer T.M., Jiga L.P., Chuang J.J., Randazzo M., Opelz G., Terness P. Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl. Int. 2005, 18(1):95-100.
3. Brown A.S., Derkits E.J. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am. J. Psychiatry 2010, 167(3):261-280.
4. Burkinshaw J., Kirman B.H., Sorsby A. Toxoplasmosis in relation to mental deficiency. Br. Med. J. 1953, 1(4812):702-704.
5. Chiarugi A., Calvani M., Meli E., Traggiai E., Moroni F. Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages. J. Neuroimmunol. 2001, 120(1-2):190-198.
6. Courret N., Darche S., Sonigo P., Milon G., Buzoni-Gatel D., Tardieux I. CD11c- and CD11b-expressing mouse leukocytes transport single Toxoplasma gondii tachyzoites to the brain. Blood 2006, 107(1):309-316.
7. Da Gama L.M., Ribeiro-Gomes F.L., Guimaraes U., Arnholdt A.C. Reduction in adhesiveness to extracellular matrix components, modulation of adhesion molecules and in vivo migration of murine macrophages infected with Toxoplasma gondii. Microbes Infect. 2004, 6(14):1287-1296.
8. Dai W., Pan H., Kwok O., Dubey J.P. Human indoleamine 2,3-dioxygenase inhibits Toxoplasma gondii growth in fibroblast cells. J. Interferon Res. 1994, 14(6):313-317.
9. Däubener W., MacKenzie C.R. IFN-gamma activated indoleamine 2,3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism. Adv. Exp. Med. Biol. 1999, 467:517-524.
10. Desmonts G., Couvreur J. Congenital toxoplasmosis. A prospective study of 378 pregnancies. N. Engl. J. Med. 1974, 290(20):1110-1116.
11. Dickerson F., Boronow J., Stallings C., Origoni A., Yolken R. Toxoplasma gondii in individuals with schizophrenia: association with clinical and demographic factors and with mortality. Schizophr. Bull. 2007, 33(3):737-740.
12. DiNatale B.C., Murray I.A., Schroeder J.C., Flaveny C.A., Lahoti T.S., Laurenzana E.M., Omiecinski C.J., Perdew G.H. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol. Sci. 2010, 115(1):89-97.
13. Dubey J.P., Speer C.A., Shen S.K., Kwok O.C., Blixt J.A. Oocyst-induced murine toxoplasmosis: life cycle, pathogenicity, and stage conversion in mice fed Toxoplasma gondii oocysts. J. Parasitol. 1997, 83(5):870-882.
14. Dubey J.P., Lindsay D.S., Speer C.A. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin. Microbiol. Rev. 1998, 11(2):267-299.
15. Engin A.B., Dogruman-Al F., Ercin U., Celebi B., Babur C., Bukan N. Oxidative stress and tryptophan degradation pattern of acute Toxoplasma gondii infection in mice. Parasitol. Res. 2012, 111(4):1725-1730.
16. Erhardt S., Olsson S.K., Engberg G. Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders. CNS Drugs 2009, 23(2):91-101.
17. Espey M.G., Chernyshev O.N., Reinhard J.F., Namboodiri M.A., Colton C.A. Activated human microglia produce the excitotoxin quinolinic acid. Neuroreport 1997, 8(2):431-434.
18. Flegr J. Effects of toxoplasma on human behavior. Schizophr. Bull. 2007, 33(3):757-760.
19. Frumento G., Rotondo R., Tonetti M., Damonte G., Benatti U., Ferrara G.B. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 2002, 196(4):459-468.
20. Fujigaki S., Saito K., Takemura M., Maekawa N., Yamada Y., Wada H., Seishima M. L-tryptophan-L-kynurenine pathway metabolism accelerated by Toxoplasma gondii infection is abolished in gamma interferon-gene-deficient mice: cross-regulation between inducible nitric oxide synthase and indoleamine-2,3-dioxygenase. Infect. Immun. 2002, 70(2):779-786.
21. Fung H.B., Kirschenbaum H.L. Treatment regimens for patients with toxoplasmic encephalitis. Clin. Ther. 1996, 18(6):1037-1056. (discussion 1036).
22. Guillemin G.J., Kerr S.J., Smythe G.A., Smith D.G., Kapoor V., Armati P.J., Croitoru J., Brew B.J. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J. Neurochem. 2001, 78(4):842-853.
23. Hermes G., Ajioka J.W., Kelly K.A., Mui E., Roberts F., Kasza K., Mayr T., Kirisits M.J., Wollmann R., Ferguson D.J., Roberts C.W., Hwang J.H., Trendler T., Kennan R.P., Suzuki Y., Reardon C., Hickey W.F., Chen L., McLeod R. Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. J. Neuroinflammation 2008, 5:48.
24. Heyes M.P., Achim C.L., Wiley C.A., Major E.O., Saito K., Markey S.P. Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem. J. 1996, 320(Pt 2):595-597.
25. Hofhuis A., van Pelt W., van Duynhoven Y.T., Nijhuis C.D., Mollema L., van der Klis F.R., Havelaar A.H., Kortbeek L.M. Decreased prevalence and age-specific risk factors for Toxoplasma gondii IgG antibodies in The Netherlands between 1995/1996 and 2006/2007. Epidemiol. Infect. 2011, 139(4):530-538.
26. Johnson A.M. Strain-dependent, route of challenge-dependent, murine susceptibility to toxoplasmosis. Z. Parasitenkd. 1984, 70(3):303-309.
27. Jones-Brando L., Torrey E.F., Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr. Res. 2003, 62(3):237-244.
28. Kannan G., Pletnikov M.V. Toxoplasma gondii and cognitive deficits in schizophrenia: an animal model perspective. Schizophr. Bull. 2012, 38(6):1155-1161.
29. Leport C., Raffi F., Matheron S., Katlama C., Regnier B., Saimot A.G., Marche C., Vedrenne C., Vilde J.L. Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy. Am. J. Med. 1988, 84(1):94-100.
30. Lu F., Huang S., Hu M.S., Kasper L.H. Experimental ocular toxoplasmosis in genetically susceptible and resistant mice. Infect. Immun. 2005, 73(8):5160-5165.
31. MacKenzie C.R., Heseler K., Muller A., Däubener W. Role of indoleamine 2,3-dioxygenase in antimicrobial defence and immuno-regulation: tryptophan depletion versus production of toxic kynurenines. Curr. Drug Metab. 2007, 8(3):237-244.
32. Mezrich J.D., Fechner J.H., Zhang X., Johnson B.P., Burlingham W.J., Bradfield C.A. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J. Immunol. 2010, 185(6):3190-3198.
33. Montoya J.G., Liesenfeld O. Toxoplasmosis. Lancet 2004, 363(9425):1965-1976.
34. Moroni F., Cozzi A., Sili M., Mannaioni G. Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J. Neural Transm. 2012, 119(2):133-139.
35. Nascimento F.S., de Rosalmeida Dantas C., Netto M.P., Mella L.F., Suzuki L.A., Banzato C.E., Rossi C.L. Prevalence of antibodies to Toxoplasma gondii in patients with schizophrenia and mood disorders. Schizophr. Res. 2012, 142(1-3):244-245.
36. Notarangelo F.M., Wu H.Q., Macherone A., Graham D.R., Schwarcz R. Gas chromatography/tandem mass spectrometry detection of extracellular kynurenine and related metabolites in normal and lesioned rat brain. Anal. Biochem. 2012, 421:573-581.
37. Pocivavsek A., Wu Q.H., Elmer G.I., Bruno J.P., Schwarcz R. Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood. Eur. J. Neurosci. 2012, 35(10):1605-1612.
38. Sathyasaikumar K.V., Stachowski E.K., Wonodi I., Roberts R.C., Rassoulpour A., McMahon R.P., Schwarcz R. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr. Bull. 2011, 37(6):1147-1156.
39. Schmidt S.K., Muller A., Heseler K., Woite C., Spekker K., MacKenzie C.R., Däubener W. Antimicrobial and immunoregulatory properties of human tryptophan 2,3-dioxygenase. Eur. J. Immunol. 2009, 39(10):2755-2764.
40. Schwarcz R., Hunter C.A. Toxoplasma gondii and schizophrenia: linkage through astrocyte-derived kynurenic acid?. Schizophr. Bull. 2007, 33(3):652-653.
41. Schwarcz R., Rassoulpour A., Wu H.Q., Medoff D., Tamminga C.A., Roberts R.C. Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry 2001, 50(7):521-530.
42. Schwarcz R., Bruno J.P., Muchowski P.J., Wu H.Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 2012, 13(7):465-477.
43. Silva N.M., Rodrigues C.V., Santoro M.M., Reis L.F., Alvarez-Leite J.I., Gazzinelli R.T. Expression of indoleamine 2,3-dioxygenase, tryptophan degradation, and kynurenine formation during in vivo infection with Toxoplasma gondii: induction by endogenous gamma interferon and requirement of interferon regulatory factor 1. Infect. Immun. 2002, 70(2):859-868.
44. Stone T.W., Stoy N., Darlington L.G. An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol. Sci. 2013, 34(2):136-143.
45. Taylor M.W., Feng G.S. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991, 5(11):2516-2522.
46. Thomas M., Pocivavsek A., Sathyasaikumar K.V., Elmer G.I., Giorgini F., Muchowski P.J., Schwarcz R. Behavioral abnormalities in mice deficient in kynurenine 3-monooxygenase: Relevance to schizophrenia. Soc. Neurosci. Abstr. 2012, 27:663.29.
47. Torrey E.F., Bartko J.J., Lun Z.R., Yolken R.H. Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. Schizophr. Bull. 2007, 33(3):729-736.
48. Torrey E.F., Bartko J.J., Yolken R.H. Toxoplasma gondii and other risk factors for schizophrenia: an update. Schizophr. Bull. 2012, 38(3):642-647.
49. Vyas A., Kim S.K., Giacomini N., Boothroyd J.C., Sapolsky R.M. Behavioral changes induced by Toxoplasma infection of rodents are highly specific to aversion of cat odors. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(15):6442-6447.
50. Wang H.L., Wang G.H., Li Q.Y., Shu C., Jiang M.S., Guo Y. Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive and Toxoplasma-seronegative schizophrenia. Acta Psychiatr. Scand. 2006, 114(1):40-48.
51. Webster J.P., Lamberton P.H., Donnelly C.A., Torrey E.F. Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii's ability to alter host behaviour. Proc. Biol. Sci. 2006, 273(1589):1023-1030.
52. Wilson E.H., Hunter C.A. The role of astrocytes in the immunopathogenesis of toxoplasmic encephalitis. Int. J. Parasitol. 2004, 34(5):543-548.
53. Wilson C.B., Remington J.S., Stagno S., Reynolds D.W. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics 1980, 66(5):767-774.
54. Wilson E.H., Wille-Reece U., Dzierszinski F., Hunter C.A. A critical role for IL-10 in limiting inflammation during toxoplasmic encephalitis. J. Neuroimmunol. 2005, 165(1-2):63-74.
55. Wonodi I., Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. Schizophr. Bull. 2010, 36(2):211-218.